Neuroglee Therapeutics is a technology company.
Neuroglee Therapeutics has raised $10.0M across 1 funding round.
Neuroglee Therapeutics has raised $10.0M in total across 1 funding round.
Neuroglee Therapeutics is a Boston-based biotechnology company founded in 2020 that develops personalized, evidence-based digital therapeutics and virtual care solutions for neurodegenerative diseases, primarily targeting mild cognitive impairment and early-stage Alzheimer's disease.[1][2][5] It offers a smartphone app for patients featuring reminiscence therapy, cognitive games, learning modules, and wellness exercises; a caregiver app; and a clinician web portal, complemented by 24/7 health navigators and partnerships like Mayo Clinic's HABIT program for early interventions.[1][3] Serving patients, families, caregivers, and clinicians—often through value-based arrangements with providers and payers—the company addresses gaps in accessible, ongoing dementia care post-diagnosis, aiming to reduce stress, improve long-term outcomes, independence, and costs while boosting member satisfaction.[3][4] Neuroglee has raised $12.3M total funding, including a $10M Series A in 2023 led by Openspace Ventures, and relocated its HQ to the US.[1][2]
Neuroglee emerged from the personal experiences of its founders with memory loss and dementia in their own families, driving a mission to transform fragmented care into comprehensive, value-based support for enduring family relationships.[3] Founded in 2020 in Boston (initially as a Singaporean startup), it was led by CEO Aniket Singh Rajput, with key team members including Jacklyn Leonardo, Nagaendran Kandiah, and Kok Pin Ng; the company later expanded its executive team in 2023 with experts in neurocognitive care, leadership, research, and data science.[1][2] A pivotal moment came via collaboration with Mayo Clinic's HABIT program, enabling digital therapeutics blending software, AI, and clinical expertise; this partnership fueled early traction, culminating in the $10M Series A shortly after joining a Singapore exchange in 2021, prompting a US HQ relocation.[1][3]
Neuroglee rides the wave of digital therapeutics and AI-driven neurology care, capitalizing on rising neurodegenerative disease prevalence (e.g., Alzheimer's affecting millions) amid shortages in specialized providers and post-diagnosis support.[1][3] Timing aligns with value-based care shifts, payer demands for cost-effective interventions, and regulatory momentum for software-as-medical-device approvals, amplified by telehealth normalization post-COVID.[3][4] Market forces like aging populations and AI advancements favor its scalable, evidence-based model over fragmented traditional care. By partnering with institutions like Mayo Clinic and integrating with primary care ecosystems, Neuroglee influences the landscape by redefining dementia management as proactive, family-centered, and payer-friendly, potentially setting standards for neurotech in value-based health systems.[1][3]
Neuroglee is poised to scale its platform through pipeline expansion into additional digital therapeutics for neurodegenerative conditions, leveraging its $12.3M funding for R&D, clinician support, and partnerships.[1][2] Trends like AI personalization, remote monitoring, and risk-based payer models will propel growth, especially as early interventions gain reimbursement traction. Its influence may evolve from niche Alzheimer's player to broader neurocare leader, enhancing ecosystem-wide outcomes if it sustains clinical validation and team expertise—ultimately fulfilling its origin vision of accessible, transformative dementia care.[3][4]
Neuroglee Therapeutics has raised $10.0M in total across 1 funding round.
Neuroglee Therapeutics's investors include m1720, Openspace Ventures.
Neuroglee Therapeutics has raised $10.0M across 1 funding round. Most recently, it raised $10.0M Series A in September 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2021 | $10.0M Series A | m1720, Openspace Ventures |